Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities

Background/Aims: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy is a clinical option for non-small cell lung cancer (NSCLC) harboring activating EGFR mutations or for cancer with wild-type (WT) EGFR when chemotherapy has failed. MET receptor activation or MET gene am...

Full description

Bibliographic Details

Published in:	Cellular Physiology and Biochemistry
Main Authors:	Wen-Yueh Hung, Jer-Hwa Chang, Yu Cheng, Chi-Kuan Chen, Ji-Qing Chen, Kuo-Tai Hua, Chao-Wen Cheng, Michael Hsiao, Chi-Li Chung, Wei-Jiunn Lee, Ming-Hsien Chien
Format:	Article
Language:	English
Published:	Cell Physiol Biochem Press GmbH & Co KG 2018-11-01
Subjects:	LECT2 EGFR MET Tumor growth Tumor invasion NSCLC
Online Access:	https://www.karger.com/Article/FullText/495233